Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Off-season doesn't allow brain to recover from football hits, study says

  • Rapid whole-brain imaging with single cell resolution

  • Trisomy 21: How an extra little chromosome throws entire genome off balance

  • Anti-seizure drug may reduce alcohol consumption, study shows

  • The ilk of human kindness: Older women with gumption score high on compassion

  • Our relationship with God changes when faced with potential romantic rejection

  • Sporting latest tech toy can make you seem more like a leader

  • Progressive neurodegenerative disorder linked to R-loop formation

  • New pain relief targets discovered by researchers

  • Better way to deal with bad memories suggested

  •